352 related articles for article (PubMed ID: 37444441)
1. Association of Myelofibrosis Phenotypes with Clinical Manifestations, Molecular Profiles, and Treatments.
Chifotides HT; Verstovsek S; Bose P
Cancers (Basel); 2023 Jun; 15(13):. PubMed ID: 37444441
[TBL] [Abstract][Full Text] [Related]
2. The Myelodepletive Phenotype in Myelofibrosis: Clinical Relevance and Therapeutic Implication.
Marcellino BK; Verstovsek S; Mascarenhas J
Clin Lymphoma Myeloma Leuk; 2020 Jul; 20(7):415-421. PubMed ID: 32199764
[TBL] [Abstract][Full Text] [Related]
3. New approaches to tackle cytopenic myelofibrosis.
Reynolds SB; Pettit K
Hematology Am Soc Hematol Educ Program; 2022 Dec; 2022(1):235-244. PubMed ID: 36485113
[TBL] [Abstract][Full Text] [Related]
4. Cytopenic myelofibrosis: prevalence, relevance, and treatment.
Vachhani P; Verstovsek S; Bose P
Expert Opin Pharmacother; 2023 Jun; 24(8):901-912. PubMed ID: 37070147
[TBL] [Abstract][Full Text] [Related]
5. Biological drivers of clinical phenotype in myelofibrosis.
Mascarenhas J; Gleitz HFE; Chifotides HT; Harrison CN; Verstovsek S; Vannucchi AM; Rampal RK; Kiladjian JJ; Vainchenker W; Hoffman R; Schneider RK; List AF
Leukemia; 2023 Feb; 37(2):255-264. PubMed ID: 36434065
[TBL] [Abstract][Full Text] [Related]
6. SOHO State of the Art Updates and Next Questions: Novel Therapeutic Strategies in Development for Myelofibrosis.
Chifotides HT; Masarova L; Verstovsek S
Clin Lymphoma Myeloma Leuk; 2023 Apr; 23(4):219-231. PubMed ID: 36797153
[TBL] [Abstract][Full Text] [Related]
7. Ruxolitinib in cytopenic myelofibrosis: Response, toxicity, drug discontinuation, and outcome.
Palandri F; Breccia M; Mazzoni C; Auteri G; Elli EM; Trawinska MM; Polverelli N; Tiribelli M; Benevolo G; Iurlo A; Tieghi A; Heidel FH; Caocci G; Beggiato E; Binotto G; Cavazzini F; Miglino M; Bosi C; Crugnola M; Bocchia M; Martino B; Pugliese N; Biondo M; Venturi M; Scaffidi L; Isidori A; Cattaneo D; Krampera M; Pane F; Cilloni D; Semenzato G; Lemoli RM; Cuneo A; Abruzzese E; Bartoletti D; Paglia S; Vianelli N; Cavo M; Bonifacio M; Palumbo GA
Cancer; 2023 Jun; 129(11):1704-1713. PubMed ID: 36932983
[TBL] [Abstract][Full Text] [Related]
8. Fedratinib, a newly approved treatment for patients with myeloproliferative neoplasm-associated myelofibrosis.
Talpaz M; Kiladjian JJ
Leukemia; 2021 Jan; 35(1):1-17. PubMed ID: 32647323
[TBL] [Abstract][Full Text] [Related]
9. Primary myelofibrosis: 2023 update on diagnosis, risk-stratification, and management.
Tefferi A
Am J Hematol; 2023 May; 98(5):801-821. PubMed ID: 36680511
[TBL] [Abstract][Full Text] [Related]
10. The Next Generation of JAK Inhibitors: an Update on Fedratinib, Momelotonib, and Pacritinib.
Patel AA; Odenike O
Curr Hematol Malig Rep; 2020 Dec; 15(6):409-418. PubMed ID: 32780250
[TBL] [Abstract][Full Text] [Related]
11. Management of myelofibrosis after ruxolitinib failure.
Harrison CN; Schaap N; Mesa RA
Ann Hematol; 2020 Jun; 99(6):1177-1191. PubMed ID: 32198525
[TBL] [Abstract][Full Text] [Related]
12. An evaluation of fedratinib for adult patients with newly diagnosed and previously treated myelofibrosis.
Saleh K; Ribrag V
Expert Rev Hematol; 2023 Apr; 16(4):227-236. PubMed ID: 36939633
[TBL] [Abstract][Full Text] [Related]
13. Novel therapeutics for myelofibrosis.
Lee SE
Blood Res; 2023 Apr; 58(S1):S13-S19. PubMed ID: 36891574
[TBL] [Abstract][Full Text] [Related]
14. Molecular Genetic Profile of Myelofibrosis: Implications in the Diagnosis, Prognosis, and Treatment Advancements.
Verma T; Papadantonakis N; Peker Barclift D; Zhang L
Cancers (Basel); 2024 Jan; 16(3):. PubMed ID: 38339265
[TBL] [Abstract][Full Text] [Related]
15. Ruxolitinib for myelofibrosis--an update of its clinical effects.
Kantarjian HM; Silver RT; Komrokji RS; Mesa RA; Tacke R; Harrison CN
Clin Lymphoma Myeloma Leuk; 2013 Dec; 13(6):638-45. PubMed ID: 24238036
[TBL] [Abstract][Full Text] [Related]
16. Changing concepts of diagnostic criteria of myeloproliferative disorders and the molecular etiology and classification of myeloproliferative neoplasms: from Dameshek 1950 to Vainchenker 2005 and beyond.
Michiels JJ; Berneman Z; Schroyens W; De Raeve H
Acta Haematol; 2015; 133(1):36-51. PubMed ID: 25116092
[TBL] [Abstract][Full Text] [Related]
17. Pacritinib and its use in the treatment of patients with myelofibrosis who have thrombocytopenia.
Diaz AE; Mesa RA
Future Oncol; 2018 Apr; 14(9):797-807. PubMed ID: 29235894
[TBL] [Abstract][Full Text] [Related]
18. Management of myelofibrosis: JAK inhibition and beyond.
Stahl M; Zeidan AM
Expert Rev Hematol; 2017 May; 10(5):459-477. PubMed ID: 28395559
[TBL] [Abstract][Full Text] [Related]
19. Momelotinib (JAK1/JAK2/ACVR1 inhibitor): mechanism of action, clinical trial reports, and therapeutic prospects beyond myelofibrosis.
Tefferi A; Pardanani A; Gangat N
Haematologica; 2023 Nov; 108(11):2919-2932. PubMed ID: 36861402
[TBL] [Abstract][Full Text] [Related]
20. Mutational landscape of blast phase myeloproliferative neoplasms (MPN-BP) and antecedent MPN.
Pasca S; Chifotides HT; Verstovsek S; Bose P
Int Rev Cell Mol Biol; 2022; 366():83-124. PubMed ID: 35153007
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
